Core Points - The board of directors of Jinlitai (300225.SZ) rejected a proposal from its largest shareholder, Hainan Dahe, to hold a temporary shareholders' meeting for the re-election of non-independent directors, with a voting result of 0 votes in favor and 5 against [1] - Hainan Dahe's ownership status is under legal dispute, leading the board to question the legitimacy of the proposal and the potential risks it poses to the company's stability if the shareholder's identity is overturned by a court ruling [3] - The board expressed concerns that the proposed candidates for non-independent directors lack relevant industry experience, which could negatively impact strategic decision-making and the professionalism of the board [3] - Jinlitai has failed to disclose its 2024 annual report within the legal deadline, which has led to an investigation by the China Securities Regulatory Commission (CSRC) and a subsequent suspension of its stock [4] Summary by Sections Shareholder Proposal - Hainan Dahe proposed to hold a temporary shareholders' meeting for the re-election of non-independent directors, but the proposal was rejected by the board [1][3] Legal and Ownership Issues - The ownership of Hainan Dahe is currently embroiled in legal disputes, raising concerns about the authenticity of their proposal and the potential impact on company stability [3] Board Composition Concerns - The board criticized the lack of industry experience among the proposed non-independent director candidates, which could hinder effective strategic decision-making [3] Financial Reporting Delays - Jinlitai's 2024 annual report was not disclosed by the planned date of April 29 due to unresolved financial verification issues, resulting in a CSRC investigation and stock suspension [4]

Group 1 - The China Securities Regulatory Commission (CSRC) encourages private equity funds to participate in mergers and acquisitions of listed companies, establishing a simplified review process for the first time [1] - The CSRC has adjusted regulatory requirements for issuing shares to purchase assets and introduced a phased payment mechanism for the first time [1] - The CSRC has introduced a "reverse linkage" arrangement for private equity funds for the first time [1] Group 2 - Multiple public fund industry insiders stated that recent analyses regarding public fund assessment benchmarks leading to market adjustments are inaccurate and lack basic knowledge and evidence [2] Group 3 - The Hong Kong Hang Seng Index will include Midea Group and ZTO Express, while BYD will join the Hang Seng Tech Index, removing Reading Group [3] Group 4 - E Fund announced that renowned fund manager Zhang Kun will no longer serve as deputy general manager due to work adjustments and will focus on investment management in the future [4] Group 5 - Jinlitai's board disagreed with shareholders' proposal to convene an extraordinary general meeting [5] - 20CM's two consecutive trading limits for Toxin Pharmaceutical: Ivos will reduce its holdings by 1.3128 million shares from March 14 to May 15, 2025 [5] - Tailing Microelectronics: The National Fund's shareholding ratio has decreased to 6.95% [5] - Two consecutive trading limits for Liren Liyang: The revenue proportion of ergotamine products is very low [5] - Tunnel Holdings: The controlling shareholder plans to increase its stake in the company by 250 million to 500 million yuan [5] - CATL announced the H-share offering price set at HKD 263.00 per share [5]

Core Viewpoint - The board of Jinlitai (300225.SZ) disagrees with the shareholder's proposal to hold an extraordinary general meeting to elect non-independent directors due to ongoing disputes over the largest shareholder's equity and the need to focus on the preparation of the 2024 annual report [1] Group 1 - The board received a proposal from shareholder Hainan Dahe to convene the second extraordinary general meeting of 2025 [1] - The board believes that the largest shareholder's equity ownership is under dispute, which complicates the situation [1] - The current board and management need to concentrate on the preparation of the annual report, which has exceeded the legal deadline for disclosure [1] Group 2 - The nominated non-independent directors lack relevant industry experience related to the company's core business [1] - The lack of experience may negatively impact the professionalism of the board's decision-making [1] - Therefore, the board decided not to agree to the proposal for the extraordinary general meeting [1]

证券代码：300225 证券简称：金力泰 公告编号：2025-027 上海金力泰化工股份有限公司 第八届董事会第五十四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议与会董事经过认真审议，通过如下决议： 1、审议未通过《关于股东提议召开临时股东大会的议案》 公司董事会于 2025 年 5 月 7 日收到海南大禾企业管理有限公司（以下简称 "海南大禾"）发来的《关于提议召开上海金力泰化工股份有限公司 2025 年第二 次临时股东大会的函》。海南大禾提请公司董事会尽快召开 2025 年第二次临时股 东大会并对非独立董事进行补选。同时要求审议以下议案： 1.《关于选举第八届董事会非独立董事的议案》 1、上海金力泰化工股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日 以电子邮件的方式发出了召开第八届董事会第五十四次（临时）会议的通知，定 于 2025 年 5 月 16 日召开第八届董事会第五十四次（临时）会议。 2、本次董事会会议应出席董事 5 名，实际出席董事 5 名；本次董事会会议 于 20 ...

之 法律意见书 二〇二五年五月 上海市海华永泰律师事务所 关于上海金力泰化工股份有限公司 不同意股东提议召开临时股东大会 地址：上海市浦东新区陆家嘴环路 1366 号富士康大厦 12 层 邮编：200120 网址: www.hiwayslaw.com 电话：021-58773177 传真：021-58773268 1 对于本法律意见书的出具，本所律师特作如下声明： （一）本所及本所律师依据《证券法》《执业办法》和《执业规则》等规定 及本法律意见书出具之日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所 认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记 载、误导性陈述或者重大遗漏，并承担相应法律责任； （二）本所律师仅对金力泰本次关于公司董事会对股东海南大禾提议召开公 司 2025 年第二次临时股东大会有关的法律专业事项发表意见，对于其他问题本所 律师不发表意见； （三）本所律师同意将本法律意见书作为公司董事会对股东海南大禾提议召 开公司 2025 年第二次临时股东大会相关事项的法律文件，随其他披露材料一起上 2 致： ...

证券代码：300225 证券简称：金力泰 公告编号：2025-028 上海金力泰化工股份有限公司 关于董事会收到公司股东提议召开临时股东大会的函 暨董事会回复意见的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东提议召开临时股东大会的基本情况 2025 年 5 月 7 日，上海金力泰化工股份有限公司（以下简称"公司"、"金 力泰公司"）董事会收到公司股东海南大禾企业管理有限公司（以下简称"海南 大禾"）发来的《关于提议召开上海金力泰化工股份有限公司 2025 年第二次临 时股东大会的函》（以下简称"《函》"），《函》主要内容如下： 公司于 2025 年 4 月 18 日披露了《关于董事、高级管理人员辞职的公告》， 于 2024 年 12 月 27 日、2023 年 3 月 15 日、2023 年 3 月 13 日披露了《关于董事 辞职的公告》。 根据《中华人民共和国公司法》《上市公司股东会规则》《上海金力泰化工 股份有限公司股东大会议事规则》及《上海金力泰化工股份有限公司章程》等规 定，为进一步完善金力泰公司的公司治理、更加有效地行使股东的监督权 ...

Core Viewpoint - The company, Shanghai Jinlitai Chemical Co., Ltd., is unable to disclose its 2024 annual report and the first quarter report of 2025 by the legal deadline of April 30, 2025, due to incomplete verification procedures related to financial information, which may lead to a risk warning for delisting [1][2][3] Progress Update - The company is actively working to complete the audit of the 2024 financial statements and is coordinating with the accounting firm to ensure timely and complete provision of necessary materials [2][5] - As of May 12, 2025, the company has not disclosed the 2024 annual report, and if it fails to do so within two months of the stock suspension, a delisting risk warning will be implemented [3] Potential Delisting Risk - The company’s stock has been suspended since May 6, 2025, and if the 2024 annual report is not disclosed within two months of this suspension, the Shenzhen Stock Exchange will decide to terminate the company's stock listing [3][4]

上海金力泰化工股份有限公司 证券代码：300225 证券简称：金力泰 公告编号：2025-026 2、根据《深圳证券交易所创业板股票上市规则》的相关规定，公司股票已 自 2025 年 5 月 6 日开市起停牌。若公司在股票停牌后两个月内仍未披露 2024 年 年度报告，公司股票交易将被实施退市风险警示；若公司在股票交易被实施退市 风险警示之日起的两个月内仍未披露 2024 年年度报告，深圳证券交易所将决定 终止公司股票上市交易。 公司原定于 2025 年 4 月 30 日披露 2024 年年度报告和 2025 年第一季度报 告。在公司 2024 年年度报告的编制及审计过程中，因涉及年度报告中财务信息 等相关重要事项未能完成核实查证程序，需公司与相关方进行多轮协调沟通，目 前相关工作仍在推进中，以上情况导致公司不能将 2024 年年度报告及 2025 年第 一季度报告依次提交至审计委员会、董事会审议。因此公司无法在法定期限内 关于定期报告披露进展暨股票交易可能被实施退市风险警 示的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、 ...

Core Viewpoint - The company Jinlitai (300225.SZ) is facing significant legal and regulatory challenges due to past false commitments made by its executives, leading to investor lawsuits and stock price declines [1][7][10]. Group 1: Legal Issues - Jinlitai is being sued by over a hundred investors for failing to fulfill a 300 million yuan share buyback commitment made by former executives, resulting in a landmark court ruling that mandates compensation for investors [1][7][10]. - The Shanghai Financial Court ruled that the executives' failure to execute their buyback promise constituted false representation, setting a precedent for similar cases in China [7][10]. - The total compensation sought by investors has reached over 52 million yuan, indicating widespread dissatisfaction among shareholders [1][10]. Group 2: Regulatory Scrutiny - The company is under investigation by the China Securities Regulatory Commission (CSRC) for violations related to its 2024 annual report and 2025 quarterly report, leading to a temporary suspension of its stock [1][2]. - Jinlitai has a history of false disclosures, having previously been penalized by the CSRC for misleading financial statements related to a fictitious gold trading business [2][3]. - The company reported significant discrepancies in its financial data, including inflated inventory and revenue figures, which have raised concerns about its financial integrity [3][4]. Group 3: Financial Performance - For 2024, Jinlitai reported total revenue of 732 million yuan, a slight decrease of 0.44% year-on-year, while net profit attributable to shareholders was 30.91 million yuan, an increase of 115.66% [5]. - The company anticipates a net profit of between 4.5 million and 6.5 million yuan for the first quarter of 2025, representing a year-on-year growth of 71% to 147% [5][6].

Investment Rating - The report does not explicitly state an investment rating for the chemical industry, but it provides detailed insights into market performance and trends, indicating a cautious outlook for certain segments [2][11]. Core Insights - In April 2025, the basic chemical index decreased by 3.61%, ranking 20th among primary industries, with various sub-sectors experiencing different levels of performance [11][16]. - The apparent consumption of methanol in China has surpassed 100 million tons for the first time, indicating significant growth in demand [2]. - The report highlights a notable increase in the prices of key chemical products, particularly trichloroethylene, which rose by 16.28% due to supply constraints and strong demand in the refrigerant market [24][25]. Market Overview - Major indices in April 2025 showed declines: Shanghai Composite Index -1.70%, Shenzhen Component Index -5.75%, and ChiNext Index -7.40% [11]. - Among the basic chemical sub-sectors, the rubber and products segment saw a significant decline of 13.52%, while daily chemicals and inorganic salts experienced growth of 8.56% and 4.37%, respectively [16][20]. Product Price Movements - The top ten products with price increases included trichloroethylene (16.28%), ammonium sulfate (12.20%), and H acid (10.96%) [24][30]. - Conversely, the products with the largest price declines included TMA (-28.26%), bromine (-24.14%), and vitamin A (-18.07%) [30][32]. Company Performance - In April 2025, 221 basic chemical companies reported positive returns, while 319 companies experienced negative returns [20]. - The top-performing companies included United Chemical with a 159.09% increase and Hongbaoli with a 104.27% increase in stock price [21][22]. Industry Trends - The report notes that the chemical raw materials and products manufacturing industry achieved a total profit of 78.76 billion yuan in the first quarter, reflecting a slight decline of 0.4% year-on-year [34]. - Shandong province is focusing on enhancing its chemical industry advantages, with significant growth in the number of large-scale chemical enterprises and revenue generation [34].